Nanomedicine review: clinical developments in liposomal applications

Esteban Beltrán-Gracia; Adolfo López-Camacho; Inocencio Higuera-Ciapara; Jesús B Velázquez-Fernández; Alba A Vallejo-Cardona

doi:10.1186/s12645-019-0055-y

Cancer Nanotechnology

Table 6 Toxicity of the clinical trials with doxorubicin

From: Nanomedicine review: clinical developments in liposomal applications

References	Disease	LF	Toxicity Grade 3–5 (%)
			Hematological				Non-hematological
			N	T	L	A	F	Na	D	V	S/M	HFS	R
Banerjee et al. (2018)	ROC	PLD	4				6		2	6	6
Lee et al. (2017)	ROC	PLD	7	3		4
Monk et al. (2017)^a	ROC	PLD					74.1			33.3			4.1
Marth et al. (2017)	ROC	PLD	15			4	5	5	5	6	6	12	2
Lindemann et al. (2017)	ROC	PLD		2		2		7		7
Herzog et al. (2016)	ROC	PLD	13			13
Runnebaum et al. (2018)	ROC	PLD + trebananib	18	10	15			5		5
Lee et al. (2017)	ROC	PLD + carboplatin	26	13		8
Sehouli et al. (2016)	ROC	PLD + carboplatin	27	15	17	10	2						2
Nagao et al. (2016)	ROC	PLD + paclitaxel + carboplatin	83	33	83	100		17			50	17
Landrum et al. (2016)	ROC	PLD + carboplatin + bevacizumab + veliparib	30	40	30
Kim et al. (2015)	ROC	PLD + carboplatin + farletuzumab	40			13	67	33	20	20		33	33
Monk et al. (2017)^a	ROC	PLD + motolimod					87.8			50.3			10.9
Marth et al. (2017)	ROC	PLD + trebananib	8			4	7	6	3	6	7	20	2
Shoji et al. (2017)	ROC	PLD + irinotecan	55	3	32	10	3	3	3	10
Thaker et al. (2017)	ROC	PLD + GEN	71		57	28					28
Herzog et al. (2016)	ROC	PLD + vintafolide	17		5						5
Jehn et al. (2016)	MBC	Caelix^®				4						12
Harbeck et al. (2016)	MBC	PLD	3	1	4	1	4				6	39
Chang et al. (2018)	MBC	PLD + cyclophosphamide	42		47	5		10		5	1
Tampaki et al. (2018)	BC	PLD + cyclophosphamide + bevacizumab + paclitaxel	24	1.6				6.5		1.6	9.7
Basho et al. (2016)	TNBC	PLD + bevacizumab + temsirolimus	8	4			4				8	13
Basho et al. (2016)	TNBC	PLD + bevacizumab + everolimus	22	11		22	22				11
Rocca et al. (2017)	BC	PLD + lapatinib							11		11	11
Coltelli et al. (2017)	BC	Myocet^® + cyclophosphamide + PTX	25					6	4	6
Cohen et al. (2018)	MM	PLD + pomalidomide + dexamethasone	51	4	38	31	9
Orlowski et al. (2016)	RMM	PLD + bortezomib
Becker et al. (2016)	MM	PLD + bortezomib + cyclophosphamide + dexamethasone	10			5			5		5	10
Voorhees et al. (2017)	RMM	PLD + bortezomib + vorinostat	37	47			16	9	19	9		9
Luminari et al. (2017)	DLBCL	Myocet^® + cyclophosphamide + vincristine + prednisone	64	8		46		2
Fridrik et al. (2016)	DLBCL	Myocet^® + cyclophosphamide + vincristine + prednisone + rituximab	50		50	85							29

In the blanks, this type of toxicity is not reported
LF liposomal formulation, N neutropenia, T thrombocytopenia, L leukopenia, A anemia, F fatigue, Na nauseas, D diarrhea, V vomiting, S/M stomatitis/mucositis, HFS hand–foot syndrome, R rash, PLD PEGylated liposomal doxorubicin, GEN an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer, ROC recurrent ovarian cancer, MBC metastatic breast cancer, BC breast cancer, TNBC triple-negative breast cancer, RMM relapse or refractory multiple myeloma, MM multiple myeloma, DLBCL relapse or refractory multiple myeloma
^aAny serious adverse event = 3.4 and 8.2% in PLD and PLD + motolimod injections, respectively

Back to article page